Lv717
5000 积分 2021-06-27 加入
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression
2小时前
已完结
Has Colorectal Cancer (c-)Met Its Match With Telisotuzumab Adizutecan?
9天前
已关闭
MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies
18天前
已完结
Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?
1个月前
已完结
Watch and Wait for Rectal Cancer: A Risky Gamble or a Safe Strategy for Patients With a Near-Complete Response?
1个月前
已关闭
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
1个月前
已完结
Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer
2个月前
已完结
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
2个月前
已完结
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease
2个月前
已完结
Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care
2个月前
已关闭
皖公网安备34019202002308
